Edition:
United States

Health News

Photo

Mylan faces scrutiny over EpiPen profit data shown to Congress Sep 26 2016

Mylan NV faced questions on Monday about the profit on its EpiPen emergency allergy treatment, following a report that the company makes 60 percent more on the injector than it had told Congress.

More Headlines

Child TB deaths set to fall as Kenya launches new drugs

NAIROBI (Thomson Reuters Foundation) - More children are likely to survive tuberculosis, the leading infectious disease killer, after Kenya introduces child-friendly medicines on Oct. 1 - the first country in the world to do so.

Sep 26 2016
Photo

Poor exercise habits may follow teens into adulthood

(Reuters Health) - Most American teenagers don’t get enough exercise, and they often stick with their sedentary ways as they enter adulthood, a U.S. study suggests.

Sep 26 2016
Photo

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.

Sep 26 2016
Photo

Pfizer decides against split-up; more deals seen likely

NEW YORK Pfizer Inc , which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines. | Video

Deals Sep 26 2016

Health Watch Graphics